|
Malignant neoplasm of breast
|
0.370 |
Biomarker
|
disease |
BEFREE |
In conclusion, our findings revealed a new mechanism of Rasal2 in the regulation of breast cancer cell proliferation via autophagy-exo-mediated pathway.
|
31473883 |
2019 |
|
Malignant neoplasm of breast
|
0.370 |
Biomarker
|
disease |
BEFREE |
The ratio of p-Rasal2/non-p-Rasal2 in ER+ and ER- breast cancers is one of the factors deciding the role of Rasal2 (or total Rasal2) as a suppressor in ER+ breast cancers or as a promoter in ER- breast cancers.
|
31759919 |
2019 |
|
Malignant neoplasm of breast
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Moreover, overexpression of RASAL2 in a breast cancer cell line rescued miR-136-mediated cell migration and invasion.
|
27108696 |
2016 |
|
Malignant neoplasm of breast
|
0.370 |
Biomarker
|
disease |
BEFREE |
Together, these results indicate that activation of a RASAL2/ARHGAP24/RAC1 module contributes to TNBC tumorigenesis and identify a context-dependent role of RASAL2 in breast cancer.
|
25384218 |
2014 |
|
Malignant neoplasm of breast
|
0.370 |
Biomarker
|
disease |
BEFREE |
RASAL2 is a GTPase activating proteins (GAPs) which was recently reported as a tumor suppressor in breast cancer.
|
25216515 |
2014 |
|
Malignant neoplasm of breast
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
In human breast cancer, RASAL2 loss is associated with metastatic disease; low RASAL2 levels correlate with recurrence of luminal B tumors; and RASAL2 ablation promotes metastasis of luminal mouse tumors.
|
24029233 |
2013 |
|
Malignant neoplasm of breast
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
In this issue of Cancer Cell, McLaughlin and colleagues report that ablation of the GasGAP gene, RASAL2, is an alternative mechanism by which Ras becomes activated in breast cancer.
|
24029223 |
2013 |
|
Malignant neoplasm of breast
|
0.370 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Colorectal Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Traditionally, RASAL2 has been regarded as a tumor suppressor but recent studies have found that it is an oncogene in specific types of cancer, such as colorectal cancer, liver cancer, triple-negative breast cancer, triple-negative/estrogen receptor-negative breast cancer.
|
31799194 |
2019 |
|
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Higher RASAL2 expression was significantly correlated with lymph node involvement and distant metastasis in CRC patients.
|
30037330 |
2018 |
|
Colorectal Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
The results of the present study indicate that RASAL2 is a potential therapeutic target to inhibit CRC progression and metastasis.
|
28454265 |
2017 |
|
Colorectal Carcinoma
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Phosphorylation of Rasal2 at Serine 237 promoted tumour growth in both ER+ and ER- tumour cells and tissues.
|
31759919 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We selected the top nine differentially expressed microRNAs, and miR135b-5p was chosen as the most important candidate for the sulforaphane-induced upregulation of the tumor suppressor gene RASAL2.
|
31044154 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Rasal2, a Ras-GTPase-activating protein (RasGAP), is a tumor suppressor in Luminal B breast cancer, frequently metastatic and recurrent.
|
31473883 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RASAL2 exhibits different relationship with clinical cancer stage, histological grade, prognosis and overall survival in different kinds of tumor.
|
31799194 |
2019 |
|
Bipolar Disorder
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder.
|
28115744 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The mRNA expression level of RASAL2 was validated by qRT-PCR, and the protein expression was evaluated by western blot as well as immunohistochemistry in CRC cell lines and primary tumors.
|
30037330 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our data indicate that RASAL2 is a tumor suppressor in BCa, and modulates cancer stemness and EMT for BCa recurrence and metastasis.
|
28182001 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RAS protein activator like 2 (RASAL2) is a RAS-GTPase-activating protein and has recently been identified to be a tumor suppressor in various types of human cancer; however, the function of RASAL2 in colorectal carcinoma (CRC) remains unclear.
|
28454265 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicated that RASAL2 serves a tumor oncogenic role in HCC and may be considered a potential target in HCC.
|
28447723 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As opposed to luminal B ER-positive breast cancers, in which RASAL2 has been shown to act as a RAS-GAP tumor suppressor, we found that RASAL2 is oncogenic in TNBC and drives mesenchymal invasion and metastasis.
|
25384218 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RASAL2 is a GTPase activating proteins (GAPs) which was recently reported as a tumor suppressor in breast cancer.
|
25216515 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In human breast cancer, RASAL2 loss is associated with metastatic disease; low RASAL2 levels correlate with recurrence of luminal B tumors; and RASAL2 ablation promotes metastasis of luminal mouse tumors.
|
24029233 |
2013 |